Sutent (sunitinib) lost US and EU patent protection years ago, so both the Pfizer brand and multiple FDA-approved generic sunitinib malate capsules are now sourceable through licensed Indian channels.
Sutent (sunitinib malate), originated by Pfizer, is now available alongside FDA-approved generic sunitinib malate capsules from manufacturers including Aurobindo, Dr. Reddy's, Sun Pharma and Teva. M Care sources both the originator brand and licensed generic lines through India's manufacturer network for hospital and tender buyers who need to choose between the two.
Sunitinib exporter and bulk supplier from India.
Sunitinib is an oral solid dose, which simplifies tender logistics considerably against injectable oncology lines: no cold chain, no reconstitution kit, no infusion set to bundle into the quote. M Care assembles bulk and tender quotes for either Sutent or generic sunitinib malate capsules in 12.5 mg, 25 mg, 37.5 mg and 50 mg strengths, with CTD/eCTD dossier support for registration in destination markets and batch-specific certificates of analysis for every shipment.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Multikinase (receptor tyrosine kinase) inhibitor, sourced and documented for export.
Sunitinib malate is an oral multikinase inhibitor. It blocks multiple receptor tyrosine kinases, including VEGFR, PDGFR and KIT, which underlies its activity against tumours dependent on angiogenesis and KIT-driven signalling.
Per the FDA label, sunitinib is indicated for gastrointestinal stromal tumour (GIST) after disease progression on or intolerance to imatinib mesylate, advanced renal cell carcinoma (RCC), adjuvant treatment of high-risk RCC following nephrectomy, and progressive, well-differentiated pancreatic neuroendocrine tumours (pNET). Destination-country labelling should be checked against this list before a tender quote is finalised, since not every market carries the adjuvant RCC indication.
It is dispensed as a hard gelatin capsule in 12.5 mg, 25 mg, 37.5 mg and 50 mg strengths, taken orally. As an oral solid dose it does not require cold-chain handling; it ships and stores as a standard ambient-temperature pharmaceutical, which keeps freight and last-mile logistics simple for GCC and African tender routes.
Active ingredient
sunitinib malate. Multikinase (receptor tyrosine kinase) inhibitor.
Forms and strengths
12.5 mg; 25 mg; 37.5 mg; 50 mg.
Indications
Indicated for gastrointestinal stromal tumour after imatinib failure or intolerance, advanced renal cell carcinoma, adjuvant high-risk renal cell carcinoma post-nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumours.
Administration
oral. Hard gelatin capsule.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Hospital oncology pharmacies, MoH cancer-centre tender desks across the GCC and Africa, licensed oncology wholesalers and importers, and NGO procurement bodies sourcing essential cancer medicines for public treatment programmes are the typical buyers for sunitinib. Because both brand and generic lines exist, tender desks often request quotes on both to compare against their formulary rules before award.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on sunitinib.
Dosing differs by indication and this matters for quote quantities. GIST and advanced RCC use Schedule 4/2: 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period, repeated in 6-week cycles. Adjuvant RCC uses the same Schedule 4/2 dosing but is capped at a maximum of 9 cycles. pNET uses a different regimen entirely: 37.5 mg once daily on a continuous schedule with no rest weeks. A pharmacy stocking sunitinib for a mixed oncology caseload needs to hold both the 37.5 mg and 50 mg strengths to cover both dosing patterns without splitting capsules, which the label does not support.
Baseline and on-treatment monitoring is not optional. Liver function tests are checked at baseline, at the start of each cycle, and as clinically indicated, because hepatotoxicity has been reported and can be severe. Left ventricular function and signs of heart failure warrant monitoring, particularly in patients with cardiac risk factors, and ECG with electrolyte correction is advised in patients at higher risk of QT prolongation. Blood pressure is checked at baseline and monitored throughout treatment, since hypertension is common on therapy. Thyroid function should be checked before starting and periodically during treatment, as thyroid dysfunction is a recognised on-treatment finding.
Hand-foot skin reaction is common enough that dispensing counselling should include it: patients should be examined for skin changes on the palms and soles, and dose interruption or reduction is part of the label's standard management pathway rather than an exception. None of this requires reconstitution or IV administration setup: sunitinib is swallowed whole, with or without food, which is worth flagging to buyers assembling patient-support materials for markets where injectable oncology handling infrastructure is limited.
Because sunitinib is oral and shelf-stable at ambient conditions, tender desks can hold larger buffer stock than they would for a cold-chain biologic without the wastage risk that drives frequent small-lot injectable orders.
The documentation pack a regulator actually asks for.
Sunitinib is a small-molecule oral solid, so its documentation chain follows standard non-biologic export practice rather than cold-chain biologic handling: batch-specific certificate of analysis, WHO-GMP manufacturing site documentation from the sourcing partner, and CDSCO export documentation from India, with CTD/eCTD dossier packages available where the destination regulator (MHRA, SFDA, MOHAP, NAFDAC, PPB, SAHPRA or an equivalent national authority) requires local registration before import.
On brand versus generic: Sutent's US and major-market patent protection has lapsed, and the FDA has approved multiple generic sunitinib malate capsule products, including from Aurobindo Pharma, Dr. Reddy's, Sun Pharmaceutical and Teva. This is not a case where M Care is limited to originator-channel supply. Buyers can request either the Pfizer-branded Sutent, sourced through licensed Indian distribution channels of the originator, or a generic sunitinib malate line from a WHO-GMP partner site, and M Care will quote both against the tender's formulary and pharmacovigilance requirements.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside sunitinib.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for sunitinib.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Sunitinib supply, the specific questions.
Is there a generic version of Sutent, or is sunitinib still patent-protected?
Sutent's patent protection has expired in the US and other major markets. The FDA has approved generic sunitinib malate capsules from several manufacturers, including Aurobindo, Dr. Reddy's, Sun Pharma and Teva. M Care can quote either the Pfizer brand or a generic line, depending on what the tender formulary specifies.
Can M Care supply Sutent (branded sunitinib) to our market?
Yes. Sutent is sourced through licensed Indian distribution channels of the originator, Pfizer. M Care handles the export documentation and dossier support needed for registration in the destination market; import basis and local registration requirements are confirmed with the buyer before dispatch.
Does sunitinib need cold-chain shipping?
No. Sunitinib is an oral hard gelatin capsule and is not a cold-chain product. It ships and stores at standard ambient pharmaceutical conditions, which simplifies freight compared with injectable oncology lines.
What strengths of sunitinib capsules can M Care supply?
12.5 mg, 25 mg, 37.5 mg and 50 mg, matching the FDA-approved Sutent and generic sunitinib malate strengths. The 50 mg strength covers Schedule 4/2 dosing for GIST and RCC; the 37.5 mg strength covers the continuous pNET regimen.
What documentation comes with a sunitinib tender order?
A batch-specific certificate of analysis, WHO-GMP site documentation from the manufacturing partner, and CDSCO export paperwork from India. CTD/eCTD dossier support is available for destination markets that require local registration before import.
Who typically buys sunitinib through M Care?
Hospital oncology pharmacies, MoH cancer-centre tender desks in the GCC and Africa, licensed oncology wholesalers, and NGO procurement bodies sourcing essential cancer medicines for public treatment programmes.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-28.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.